The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
D'IncalciM., GalmariniC.M.A review of trabectedin (ET-743): A unique mechanism of action. Mol Cancer Ther.2010; 9(8): 2157–2163.
2.
UedaT., KakunagaS., AndoM.. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs.2014; 32(4): 691–699.
3.
Garcia-CarboneroR., SupkoJ.G., ManolaJ.. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol.2004; 22(8): 1480–1490.
ForouzeshB., HidalgoM., ChuQ.. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res.2009; 15(10): 3591–3599.
6.
ChukM.K., AikinA., WhitcombT.. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer.2012; 59(5): 865–869.
7.
MachielsJ.P., StaddonA., HerremansC.. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: Open-label, multicenter studies. Cancer Chemother Pharmacol.2014; 74(4): 729–737.
8.
PardoB., SalazarR., CiruelosE.. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. Med Oncol.2012; 29(3): 2240–2250.
9.
DemetriG.D., ChawlaS.P., von MehrenM.. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol.2009; 27(25): 4188–4196.
10.
Le CesneA., YovineA., BlayJ.Y.. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs.2012; 30(3): 1193–1202.
11.
MichaelsonM.D., BellmuntJ., HudesG.R.. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol.2012; 23(5): 1234–1240.
12.
GoldsteinL.J., GurtlerJ., Del PreteS.A.. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: A multicenter, randomized, phase II study comparing 2 administration regimens. Clin Breast Cancer.2014; 14(6): 396–404.
13.
KrasnerC.N., McMeekinD.S., ChanS.. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer.2007; 97(12): 1618–1624.
14.
Paz-AresL., Rivera-HerrerosF., Díaz-RubioE.. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. Clin Colorectal Cancer.2007; 6(7): 522–528.
15.
SessaC., De BraudF., PerottiA.. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncl.2005; 23(9): 1867–1874.
16.
Del CampoJ.M., RoszakA., BidzinskiM.. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol.2009; 20(11): 1794–1802.
17.
McMeekinD.S., LisyanskayaA., CrispensM.. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study. Gynecol Oncol.2009; 114(2): 288–292.
18.
MassutiB., CoboM., CampsC.. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 under-expression and pretreated with platinum. Lung Cancer.2012; 76(3): 3543–3561.
19.
Paz-AresL., López-PousaA., PovedaA.. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone. Invest New Drugs.2012; 30(2): 729–740.
20.
DelalogeS., Wolp-DinizR., ByrskiT.. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: Results of an international first-in-class phase II study. Ann Oncol.2014; 25(6): 1152–1158.
21.
Bui-NguyenB., ButrynskiJ.E., PenelN.. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. Eur J Cancer.2015; 51(10): 1312–1320.
22.
RoylanceR., SeddonB., McTiernanA.. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Clin Oncol (R Coll Radiol).2007; 19(8): 572–576.
23.
SanfilippoR., GrossoF., JonesR.L.. Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecol Oncol.2011; 123(3): 553–556.
24.
KawaiA., ArakiN., SugiuraH., Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study. Lancet Oncol.2015; 16(4): 406–416.
25.
BaruchelS., PappoA., KrailoM.. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur J Cancer.2012; 48(4): 579–85.
26.
BlayJ.Y., Le CesneA., VerweijJ.. A phase II study of ET-743/trabectedin (“Yondelis”) for patients with advanced gastrointestinal stromal tumours. Eur J Cancer.2004; 40(9): 1327–1331.
27.
YovineA., RiofrioM., BlayJ.Y.. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol.2004; 22(5): 890–899.
28.
Garcia-CarboneroR., SupkoJ.G., MakiR.G.. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study. J Clin Oncol.2005; 23(24): 5484–5492.
29.
Le CesneA., BlayJ.Y., JudsonI.. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol.2005; 23(3): 576–584.
30.
ZelekL., YovineA., BrainE.. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer.2006; 94(11): 1610–1614.
31.
FayetteJ., BoyleH., ChabaudS.. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: Analysis of 92 patients treated in a single institution. Anticancer Drugs.2010; 21(1): 113–119.
32.
GronchiA., BuiB.N., BonvalotS.. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol.2012; 23(3): 771–776.
33.
MonkB.J., BlessingJ.A., StreetD.G.. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol.2012; 124(1): 48–52.
34.
SamuelsB.L., ChawlaS., PatelS.. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: Results of a worldwide expanded access program study. Ann Oncol.2013; 24(6): 1703–1709.
35.
BlayJ.Y., LeahyM.G., NguyenB.B.. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer.2014; 50(6): 1137–1147.
36.
BlayJ.Y., CasaliP., NietoA.. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. Future Oncol.2014; 10(1): 59–68.
37.
Le CesneA., BlayJ.Y., DomontJ.. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): A randomised phase 2 trial. Lancet Oncol.2015; 16(3): 312–319.
38.
ReyesP., HeidelbergerC.Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol.1965; 1(1): 14–30.
39.
SantiD.V., SakaiT.T.Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′ - deoxyuridylic acid. Biochemistry.1971; 10(19): 3598–3607.
40.
TemminkO.H., ComijnE.M., FukushimaM.. Intra-cellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids.2004; 23(8–9): 1491–1494.
41.
FujiwaraY., HeidelbergerC.Fluorinated pyrimidines. 38. The incorporation of 5-trifluoromethyl-2′ - deoxyuridine into the deoxyribonucleic acid of vaccinia virus. Mol Pharmacol.1970; 6(3): 281–291.
42.
MatsushitaS., NitandaT., FurukawaT.. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res.1999; 59(8): 1911–1916.
43.
FukushimaM., SuzukiN., EmuraT.. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′ - deoxyribonucleosides. Biochem Pharmacol.2000; 59(10): 1227–1236.
44.
HongD.S., AbbruzzeseJ.L., BogaardK.. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer2006; 107(6): 1383–1390.
45.
Lonsurf [prescribing information].Princeton, NJ: Taiho Oncology, Inc. (U.S.); 2015.
46.
DoiT., OhtsuA., YoshinoT.. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer.2012; 107(3): 429–434.
47.
PatelM.R., BendellJ.C., MayerR.J.. A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC) [abstract 3631]. Proc Am Soc Clin Oncol.2012. http://meetinglibrary.asco.org/print/565697. Accessed November 3, 2015.
48.
YoshinoT., MizunumaN., YamazakiK.. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase II trial. Lancet Oncol.2012; 13(10): 993–1001.
49.
MayerR.J., Van CutsemE., FalconeA.. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med.2015; 372(20): 1909–1919.
50.
GreenM.C., PusztaiL., TheriaultL.R.. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC) [abstract 10576]. Proc Am Soc Clin Oncol.2006. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/10576?sid=-91d048f7-f9be-4816-9089-f2c4e97547a6. Accessed November 3, 2015.
51.
OvermanM.J., KopetzS., VaradhacharyG.. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest.2008; 26(8): 794–799.
